Journal of Medical Cases, ISSN 1923-4155 print, 1923-4163 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Med Cases and Elmer Press Inc
Journal website https://jmc.elmerpub.com

Case Report

Volume 17, Number 5, May 2026, pages 231-237

Challenges of Hepatitis B Virus Reactivation and CD19 Testing Following Tafasitamab Plus Lenalidomide for Relapsed Diffuse Large B-Cell Lymphoma

Figures

↓  Figure 1. Positron emission tomography scan at diagnosis revealed lymphoma involvement at multiple nodal areas (left nasopharyngeal, right iliac, right femoral) and vertebral spine (arrowheads).
Figure 1.
↓  Figure 2. Bone marrow flow cytometry at cycle 10 day 6 of tafasitamab plus lenalidomide showed a small population of CD19-negative B cells (purple, 440 events, 0.16%) expressing CD20 and surface kappa light chain. Plasma cells are nearly depleted (15 events, 0.01% of marrow cells).
Figure 2.
↓  Figure 3. The summary of the patient’s lymphoma and HBV treatment course. Images and laboratory exams of disease diagnosis and staging are shown in the upper part. Lymphoma treatment regimens are shown in the middle, whereas viral hepatitis profiles and HBV treatments are summarized in the lower part. BM: bone marrow; HBV: hepatitis B virus; LN: lymph node; R-square: rituximab plus lenalidomide.
Figure 3.